跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PRADAXA 30 MG GRANULADO RECUBIERTO - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
PRADAXA 30 MG GRANULADO RECUBIERTO
Approved
STANDARD
PRADAXA 30 MG GRANULADO RECUBIERTO
Boehringer Ingelheim International Gmbh
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Mar 8, 2022
Approval ID
19b6975e7a9fd129
Company
Boehringer Ingelheim International Gmbh
Type
Standard
Approval Details
Approval Id
19b6975e7a9fd129
Drug Cima Aemps Name
PRADAXA 30 MG GRANULADO RECUBIERTO
Register Number
108442026
Holder Company Name
Boehringer Ingelheim International Gmbh
Marketing Company Name
Boehringer Ingelheim Espana S.A.
Holder Company Detail Path
/organization/boehringer-ingelheim-international-gmbh
Authorization Date
2022-03-08
Dosage Form
GRANULADO RECUBIERTO
Dose
30 mg
Route Of Administration
VÍA ORAL
Prescription Type
Diagnóstico Hospitalario
Commercialized
Yes
Company Name
Boehringer Ingelheim International Gmbh
Company Detail Path
/organization/boehringer-ingelheim-international-gmbh
Company Information
Pharmaceutical Company Name
Boehringer Ingelheim International GmbH
Country Name
Germany
City Name
ingelheim am rhein,rheinland-pfalz,country_de
Address
Binger Straße 173
Website
http://www.boehringer-ingelheim.com
Active Ingredients
DABIGATRAN ETEXILATO MESILATO
34,59 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Mar 8, 2022
Approval ID
19b6975e7a9fd129
Type
Standard
Back to CIMA-AEMPS Approvals